Please enable JavaScript to continue using this application.

Compare $KLRA vs $RARE | Chartloom

Compare

$KLRA vs $RARE

Kailera Therapeutics Inc · Ultragenyx Pharmaceutical Inc

KLRA

Kailera Therapeutics Inc

RARE

Ultragenyx Pharmaceutical Inc

Compare $KLRA vs $RARE

Comparing Kailera Therapeutics Inc and Ultragenyx Pharmaceutical Inc

KLRAKailera Therapeutics Inc

RAREUltragenyx Pharmaceutical Inc

KLRAKailera Therapeutics Inc

Market cap

$1.50B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-55.3%

52W performance

-55.3%

FCF yield

0.0%

RAREUltragenyx Pharmaceutical Inc

Market cap

$1.52B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

1.74x

Rev growth (TTM)

17.5%

YTD performance

-34.4%

52W performance

-49.8%

FCF yield

-32.4%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

KLRA

RARE

Detailed metrics comparison

KLRA

Kailera Therapeutics Inc

RARE

Ultragenyx Pharmaceutical Inc

Market Cap

KLRA$1.50B

RARE$1.52B

Enterprise Value

KLRA$1.37B

RARE$2.54B

Price

KLRA$11.61

RARE$15.48

P/E Ratio

KLRAN/A

RAREN/A

P/S Ratio

KLRA0.00x

RARE2.13x

EV/Sales

KLRA0.00x

RARE3.54x

EV/EBITDA

KLRA0.00x

RARE0.00x

P/B Ratio

KLRA1.20x

RARE163.83x

P/FCF Ratio

KLRAN/A

RAREN/A

EV/FCF

KLRA0.00x

RARE-5.14x

PEG Ratio

KLRAN/A

RAREN/A

Forward P/E (NTM)

KLRAN/A

RAREN/A

Forward P/S (NTM)

KLRAN/A

RARE1.74x

Revenue (TTM)

KLRA$0

RARE$717M

Revenue Growth (YoY)

KLRAN/A

RARE17.5%

Forward Rev Growth

KLRA275.8%

RARE27.7%

Gross Margin (TTM)

KLRA0.0%

RARE83.1%

Operating Margin (TTM)

KLRA0.0%

RARE0.0%

EBITDA Margin (TTM)

KLRA0.0%

RARE-69.0%

Net Margin (TTM)

KLRA0.0%

RARE-81.7%

FCF Margin (TTM)

KLRAN/A

RARE-68.9%

Net Income (TTM)

KLRA$-190M

RARE$-586M

FCF (TTM)

KLRA$0

RARE$-494M

EPS (TTM)

KLRA-$1.86

RARE-$5.75

ROE (TTM)

KLRA0.0%

RARE-41417.0%

ROA (TTM)

KLRA0.0%

RARE-4437.0%

ROIC (TTM)

KLRA0.0%

RARE-5861.0%

Cash

KLRA$130M

RARE$125M

Debt

KLRA$0

RARE$1.14B

Net Cash/Debt

KLRA$130M

RARE$-1.02B

Current Ratio (TTM)

KLRA11.11x

RARE1.73x

Quick Ratio (TTM)

KLRA11.04x

RARE1.43x

Debt/Equity (TTM)

KLRA0.00x

RARE90.54x

Debt/Assets (TTM)

KLRA0.0%

RARE0.0%

Interest Coverage (TTM)

KLRAN/A

RAREN/A

Net Debt/EBITDA (TTM)

KLRA0.00x

RARE0.00x

Beta

KLRA2.22

RARE0.35

52W Performance

KLRA-55.3%

RARE-49.8%

YTD Performance

KLRA-55.3%

RARE-34.4%

% from 52W High

KLRA-58.9%

RARE-61.2%

% from 52W Low

KLRA19.0%

RARE21.6%

Asset Turnover (TTM)

KLRA0.00x

RARE0.54x

FCF Yield (TTM)

KLRA0.0%

RARE-32.4%

Earnings Yield (TTM)

KLRA-12.6%

RARE-38.4%

Dividend Yield (TTM)

KLRAN/A

RAREN/A

Rule of 40

KLRA0.0

RARE-51.4

EV/GP/RG

KLRAN/A

RARE0.17

Ticker research

View KLRA research View RARE research

Metric	KLRA Kailera Therapeutics Inc	RARE Ultragenyx Pharmaceutical Inc
Market & Valuation
Market Cap	$1.50B	$1.52B
Enterprise Value	$1.37B	$2.54B
Price	$11.61	$15.48
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	2.13x
EV/Sales	0.00x	3.54x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.20x	163.83x
P/FCF Ratio	N/A	N/A
EV/FCF	0.00x	-5.14x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	1.74x
Revenue & Growth
Revenue (TTM)	$0	$717M
Revenue Growth (YoY)	N/A	17.5%
Forward Rev Growth	275.8%	27.7%
Profitability
Gross Margin (TTM)	0.0%	83.1%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-69.0%
Net Margin (TTM)	0.0%	-81.7%
FCF Margin (TTM)	N/A	-68.9%
Net Income (TTM)	$-190M	$-586M
FCF (TTM)	$0	$-494M
EPS (TTM)	-$1.86	-$5.75
ROE (TTM)	0.0%	-41417.0%
ROA (TTM)	0.0%	-4437.0%
ROIC (TTM)	0.0%	-5861.0%
Financial Health
Cash	$130M	$125M
Debt	$0	$1.14B
Net Cash/Debt	$130M	$-1.02B
Current Ratio (TTM)	11.11x	1.73x
Quick Ratio (TTM)	11.04x	1.43x
Debt/Equity (TTM)	0.00x	90.54x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.22	0.35
52W Performance	-55.3%	-49.8%
YTD Performance	-55.3%	-34.4%
% from 52W High	-58.9%	-61.2%
% from 52W Low	19.0%	21.6%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.54x
FCF Yield (TTM)	0.0%	-32.4%
Earnings Yield (TTM)	-12.6%	-38.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-51.4
EV/GP/RG	N/A	0.17
Ticker research	View KLRA research	View RARE research

Valuation

P/S Ratio

KLRA

0.00x

RARE

2.13x

EV/FCF

RARE

-5.14x

KLRA

0.00x

Growth & revenue

Revenue Growth TTM

RARE

17.5%

Forward Revenue Growth

KLRA

275.8%

RARE

27.7%

Profitability & performance

Gross Margin

RARE

83.1%

KLRA

0.0%

ROE

KLRA

0.0%

RARE

-41417.0%

FCF Yield %

KLRA

0.0%

RARE

-32.4%

52-Week Performance

RARE

-49.8%

KLRA

-55.3%

Detailed metrics comparison

KLRA

Kailera Therapeutics Inc

RARE

Ultragenyx Pharmaceutical Inc

Market Cap

KLRA$1.50B

RARE$1.52B

Enterprise Value

KLRA$1.37B

RARE$2.54B

Price

KLRA$11.61

RARE$15.48

P/E Ratio

KLRAN/A

RAREN/A

P/S Ratio

KLRA0.00x

RARE2.13x

EV/Sales

KLRA0.00x

RARE3.54x

EV/EBITDA

KLRA0.00x

RARE0.00x

P/B Ratio

KLRA1.20x

RARE163.83x

P/FCF Ratio

KLRAN/A

RAREN/A

EV/FCF

KLRA0.00x

RARE-5.14x

PEG Ratio

KLRAN/A

RAREN/A

Forward P/E (NTM)

KLRAN/A

RAREN/A

Forward P/S (NTM)

KLRAN/A

RARE1.74x

Revenue (TTM)

KLRA$0

RARE$717M

Revenue Growth (YoY)

KLRAN/A

RARE17.5%

Forward Rev Growth

KLRA275.8%

RARE27.7%

Gross Margin (TTM)

KLRA0.0%

RARE83.1%

Operating Margin (TTM)

KLRA0.0%

RARE0.0%

EBITDA Margin (TTM)

KLRA0.0%

RARE-69.0%

Net Margin (TTM)

KLRA0.0%

RARE-81.7%

FCF Margin (TTM)

KLRAN/A

RARE-68.9%

Net Income (TTM)

KLRA$-190M

RARE$-586M

FCF (TTM)

KLRA$0

RARE$-494M

EPS (TTM)

KLRA-$1.86

RARE-$5.75

ROE (TTM)

KLRA0.0%

RARE-41417.0%

ROA (TTM)

KLRA0.0%

RARE-4437.0%

ROIC (TTM)

KLRA0.0%

RARE-5861.0%

Cash

KLRA$130M

RARE$125M

Debt

KLRA$0

RARE$1.14B

Net Cash/Debt

KLRA$130M

RARE$-1.02B

Current Ratio (TTM)

KLRA11.11x

RARE1.73x

Quick Ratio (TTM)

KLRA11.04x

RARE1.43x

Debt/Equity (TTM)

KLRA0.00x

RARE90.54x

Debt/Assets (TTM)

KLRA0.0%

RARE0.0%

Interest Coverage (TTM)

KLRAN/A

RAREN/A

Net Debt/EBITDA (TTM)

KLRA0.00x

RARE0.00x

Beta

KLRA2.22

RARE0.35

52W Performance

KLRA-55.3%

RARE-49.8%

YTD Performance

KLRA-55.3%

RARE-34.4%

% from 52W High

KLRA-58.9%

RARE-61.2%

% from 52W Low

KLRA19.0%

RARE21.6%

Asset Turnover (TTM)

KLRA0.00x

RARE0.54x

FCF Yield (TTM)

KLRA0.0%

RARE-32.4%

Earnings Yield (TTM)

KLRA-12.6%

RARE-38.4%

Dividend Yield (TTM)

KLRAN/A

RAREN/A

Rule of 40

KLRA0.0

RARE-51.4

EV/GP/RG

KLRAN/A

RARE0.17

Ticker research

View KLRA research View RARE research

Metric	KLRA Kailera Therapeutics Inc	RARE Ultragenyx Pharmaceutical Inc
Market & Valuation
Market Cap	$1.50B	$1.52B
Enterprise Value	$1.37B	$2.54B
Price	$11.61	$15.48
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	2.13x
EV/Sales	0.00x	3.54x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.20x	163.83x
P/FCF Ratio	N/A	N/A
EV/FCF	0.00x	-5.14x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	1.74x
Revenue & Growth
Revenue (TTM)	$0	$717M
Revenue Growth (YoY)	N/A	17.5%
Forward Rev Growth	275.8%	27.7%
Profitability
Gross Margin (TTM)	0.0%	83.1%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-69.0%
Net Margin (TTM)	0.0%	-81.7%
FCF Margin (TTM)	N/A	-68.9%
Net Income (TTM)	$-190M	$-586M
FCF (TTM)	$0	$-494M
EPS (TTM)	-$1.86	-$5.75
ROE (TTM)	0.0%	-41417.0%
ROA (TTM)	0.0%	-4437.0%
ROIC (TTM)	0.0%	-5861.0%
Financial Health
Cash	$130M	$125M
Debt	$0	$1.14B
Net Cash/Debt	$130M	$-1.02B
Current Ratio (TTM)	11.11x	1.73x
Quick Ratio (TTM)	11.04x	1.43x
Debt/Equity (TTM)	0.00x	90.54x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.22	0.35
52W Performance	-55.3%	-49.8%
YTD Performance	-55.3%	-34.4%
% from 52W High	-58.9%	-61.2%
% from 52W Low	19.0%	21.6%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.54x
FCF Yield (TTM)	0.0%	-32.4%
Earnings Yield (TTM)	-12.6%	-38.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-51.4
EV/GP/RG	N/A	0.17
Ticker research	View KLRA research	View RARE research